Clinical and genomic features of SPOP ‐mutant prostate cancer-Reference-Cited by-同舟云学术

Clinical and genomic features of SPOP ‐mutant prostate cancer

Published:2021-11-15 Issue:2 Volume:82 Page:260-268
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Nakazawa Mari¹^ORCID,Fang Mike²^ORCID,H. Marshall Catherine³^ORCID,Lotan Tamara L.³⁴⁵^ORCID,Isaacsson Velho Pedro³⁶^ORCID,Antonarakis Emmanuel S.⁷^ORCID

Affiliation:

1. Department of Medicine Johns Hopkins School of Medicine Baltimore Maryland USA

2. Department of Population and Quantitative Health Sciences Case Western Reserve University Cleveland Ohio USA

3. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of Medicine Baltimore Maryland USA

4. Department of Pathology Johns Hopkins School of Medicine Baltimore Maryland USA

5. Department of Urology Johns Hopkins University School of Medicine Baltimore Maryland USA

6. Department of Oncology Moinhos de Vento Hospital Porto Alegre Brazil

7. Department of Oncology, Masonic Cancer Center University of Minnesota Medical Center Minneapolis Minnesota USA

Funder

Foundation for the National Institutes of Health

U.S. Department of Defense

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24269

Reference46 articles.

1. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

2. SPOP promotes transcriptional expression of DNA repair and replication factors to prevent replication stress and genomic instability

3. SPOP mutation leads to genomic instability in prostate cancer;Boysen G;eLife,2015

4. Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer

5. SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer;Prostate Cancer and Prostatic Diseases;2024-07-17

2. Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access;American Society of Clinical Oncology Educational Book;2024-06

3. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer;European Urology Oncology;2024-06

4. Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis;European Urology Oncology;2024-05

5. Multiplexed quantitative proteomics in prostate cancer biomarker development;Advances in Cancer Research;2024